WHO and the Population Division of the United Nations Department of Economic and Social Affairs have launched a new, open-access database of laws, policies and health standards on abortion in countries worldwide. The database aims to promote greater transparency of abortion laws and policies, as well as to improve countries’ accountability for the protection of women and girls’ health and human rights.
Dune Medical, which markets a tool that spots residual breast cancer cells following a lumpectomy, has raised $12.3 million. The funds will drive the development of the company’s technology for other types of cancer.
A team led by Gang Han, PhD, has designed a human protein-based, tumor-targeting Magnetic Resonance Imaging (MRI) contrast that can be easily cleared by the body. The discovery holds promise for clinical application, including early stage tumor detection because of the enhanced MRI contrast, according to Dr. Han, associate professor of biochemistry & molecular pharmacology at University of Massachusetts Medical School.
The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
In a study conducted at York University, scientists came to the astonishing conclusion that beta blockers could protect against heart failure. This was one of the latest discoveries in a field with endless treatments managing symptoms though previously damage sustained to the heart can’t be revered.
Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.